# Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

> **NCT03040726** · PHASE2,PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 53 (actual)

## Conditions studied

- Malignant Neoplasm
- Nausea
- Vomiting

## Interventions

- **DRUG:** Netupitant
- **DRUG:** Palonosetron
- **DRUG:** Palonosetron Hydrochloride
- **OTHER:** Placebo
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03040726
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-03
- **Primary completion:** 2022-02-14
- **Final completion:** 2022-02-14
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2023-10-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03040726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03040726, "Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03040726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*